

---

## **Groundbreaking research cooperation: The Medi-Globe Group and the IHU in Strasbourg are developing the world's first AI software for detecting pancreatic diseases**

The Medi-Globe Group becomes industrial partner of the Institut Hospitalo-Universitaire Strasbourg (IHU)

**Achenmühle, April 29, 2022.** The Medi-Globe Group, based in Bavaria, has entered into a groundbreaking research cooperation with the French Institut Hospitalo-Universitaire (IHU) in Strasbourg. The goal of the collaboration is the world's first AI software for detecting diseases of the pancreas in endoscopic ultrasound examinations. As industrial partner of the renowned IHU, the Medi-Globe Group is thus further expanding its role as an innovation leader in minimally invasive diagnostics and therapies.

Medi-Globe Group CEO Martin Lehner: "Together with the researchers at the IHU in Strasbourg, we will develop the world's first software for the diagnosis of diseases of the pancreas to market maturity. The key technology here is artificial intelligence."

"We are delighted to announce this special partnership with the Medi-Globe Group. This collaboration is an important step in realizing our goal of being a technology leader in the application of artificial intelligence in the field of early detection of pancreatic diseases. Since the founding of IHU Strasbourg, our vision has been to provide technologies that help physicians achieve the best outcome for their patients," explains Benoit Gallix, CEO of IHU Strasbourg.

### **Important milestone in the diagnosis of pancreatic cancer in sight**

Diseases of the pancreas can have serious consequences for patients and are difficult to diagnose for physicians. Early detection is crucial for the patient's chance of survival. Today in Europe more than 90 percent of patients with pancreatic cancer die.

"In the future, with the support of artificial intelligence, we will be able to make the experience of the world's leading gastroenterologists available to all physicians. Our successful cooperation with the IHU and leading international university hospitals has the potential to revolutionize the diagnosis of pancreatic diseases and, above all, the diagnosis of pancreatic cancer" says Marc Jablonowski, Chief Technology & Innovation Officer (CTIO) of the Medi-Globe Group.

### **About Medi-Globe Group**

The Medi-Globe Group is an innovative, fast-growing and internationally oriented medical technology group in the fields of urology, gastroenterology and pneumology. The head office is in Achenmuehle in Chiemgau, Bavaria, around 70 kilometers south of Munich. Around 670 employees work for the Medi-Globe Group, which was founded in 1990, in Germany, France, the Czech Republic, China, Brazil, the Netherlands and Austria. Customers include university clinics, specialist clinics, special medical facilities and specialists in gastroenterology, urology and pneumology in around 120 countries worldwide. The managing directors are Martin Lehner (CEO), Christian Klein (COO), Dr. Nikolaus König (CFO) and Marc Jablonowski (CTIO).

**Contact:**

Medi-Globe Group  
Carola Zollmann  
[press@medi-globe.de](mailto:press@medi-globe.de)

braun communications  
Stefanie Braun  
+49 171 2 888 214  
[sb@brauncommunications.de](mailto:sb@brauncommunications.de)